Bli medlem
Bli medlem

Du är här




17 November 2016, 15:00 CET


Mechelen, Belgium
,17 November
2016 -
Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular
diagnostics company (Euronext Brussels: BCART), announced today that it
successfully raised an amount of €32,674,281.85 in gross proceeds by means of
a private placement via an accelerated bookbuild offering of 4,058,917 new
shares (being approximately 10% of the Company's outstanding shares) at an
issue price of €8.05 per share (the "Offering"). The closing price of the
Company's shares prior to the launch of the Offering, on 16 November 2016,
was €8.25 per share.

Ewoud Welten, Chief Financial Officer of Biocartis, commented
: "We are very pleased to announce the successful completion of this private
placement at a low discount which reflects the strong demand from local and
international investors that we experienced during a very smooth,
oversubscribed bookbuild process. Our cash position is now further
strengthened, allowing us to continue the global expansion of our installed
base of Idylla(TM) instruments and development of new tests. We are grateful
for the ongoing support by existing shareholders and welcome our new

The net proceeds of the Offering will be used to fund the development,
regulatory approvals and launches of new tests and applications for
Biocartis' Idylla(TM) platform, to fund the expansion of its sales and
marketing team to support the global roll-out of its products, to fund the
expansion of Biocartis' cartridge manufacturing capacity, and for general
corporate purposes.

Degroof Petercam, KBC Securities and Kempen&Co acted as Joint Bookrunners in
the Offering.

In relation to the Offering, the Company has agreed with the Joint Bookrunners
to a market customary 90-days standstill period on future share issuances,
waivable by the Joint Bookrunners.

The payment and delivery of the new shares is expected to take place on 21
November 2016, and an application will be made to admit the new shares to
trading on the regulated market of Euronext Brussels at the same time. The
new shares to be issued will have the same rights and benefits as, and rank
pari passu in all respects with, the existing and outstanding shares of
Biocartis at the moment of their issuance.

As a result of the issuance of new shares, the Company's share capital will
increase from €405,891.88 to €446,481.05 and its issued and outstanding
shares will increase from 40,589,188 to 44,648,105 ordinary shares.

--- END ---

More information:

Renate Degrave
Manager Corporate Communications&Investor Relations

tel +32 15 631 729
mobile +32 471 53 60 64

About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at
improving clinical practice for the benefit of patients, clinicians, payers
and industry. Biocartis' proprietary MDx Idylla(TM) platform is a fully
automated sample-to-result, real-time PCR (Polymerase Chain Reaction) system
that offers accurate, highly reliable molecular information from virtually
any biological sample in virtually any setting. Biocartis launched the
Idylla(TM) platform in September 2014. Biocartis is developing and marketing
a rapidly expanding test menu addressing key unmet clinical needs in oncology
and infectious diseases. These areas represent respectively the fastest
growing and largest segments of the MDx market worldwide. Today, Biocartis
has five oncology tests and two infectious disease tests on the market. More
information: Photo Library availablehere. Follow us
onTwitter: @Biocartis_.

Important information:

This communication is not a prospectus for the purposes of the Prospectus
Directive (Directive 2003/71/EC and amendments thereto, including Directive
2010/73/EU, to the extent implemented in the relevant Member State of the
EEA) and any implementing measure in each relevant Member State of the EEA
(the 'Prospectus Directive'). This communication cannot be used as basis for
any investment agreement or decision. Acquiring investments to which this
announcement relates may expose an investor to a significant risk of losing
the entire amount invested. Persons considering making such investments
should consult an authorised person specialising in advising on such
investments. This announcement does not constitute a recommendation
concerning the securities referred to herein.

The information contained in this announcement is for general information only
and does not purport to be full or complete. This announcement does not
constitute, or form part of, an offer to sell or issue, or any solicitation
of an offer to purchase or subscribe for shares, and any purchase of,
subscription for or application for, shares. This announcement and the
information contained herein are not for publication, distribution or release
in, or into, the United States, Australia, Canada, Japan, South Africa or any
other jurisdiction where to do so would be prohibited by applicable law. Any
persons reading this announcement should inform themselves of and observe any
such restrictions.

This announcement is not for distribution, directly or indirectly, in or into
the United States. It does not constitute or form a part of any offer or
solicitation to purchase or subscribe for securities in the United States.
The securities mentioned herein have not been, and will not be, registered
under the U.S. Securities Act of 1933, as amended (the 'Securities Act') and
may not be offered or sold in the United States, except pursuant to an
exemption from the registration requirements of the Securities Act. The
Company and its affiliates have not registered, and do not intend to
register, any portion of the offering of the securities concerned in the
United States, and do not intend to conduct a public offering of securities
in the United States.

An offer of securities to which this announcement relates is only addressed to
and directed at persons in member states of the European Economic Area
('EEA') who are 'qualified investors' within the meaning of Article 2(1)(e)
of the Prospectus Directive ('Qualified Investors'), or such other investors
as shall not constitute an offer to the public within the meaning of Article
3.1 of the Prospectus Directive. In addition, any offer of securities to
which this announcement relates is in the United Kingdom being distributed
only to, and is directed only at, (i) persons who have professional
experience in matters relating to investments falling within Article 19(5) of
the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005,
as amended (the 'Order'), (ii) high net worth entities etc. falling within
Article 49(2)(a) to (d) of the Order, and (iii) any other person to whom it
may otherwise lawfully be communicated (all such persons together being
referred to as 'relevant persons'). The offering of securities to which this
announcement relates will only be available to, and any invitation, offer or
agreement to subscribe for, purchase, or otherwise acquire securities will be
engaged in only with relevant persons. Any person who is not a relevant
person should not act or rely on this announcement or any of its contents.

No announcement or information regarding the offering, listing or securities
of the Company referred to above may be disseminated to the public in
jurisdictions where a prior registration or approval is required for such
purpose. No steps have been taken, or will be taken, for the offering or
listing of securities of the Company in any jurisdiction outside of Belgium
where such steps would be required. The issue, exercise, or sale of, and the
subscription for or purchase of, securities of the Company are subject to
special legal or statutory restrictions in certain jurisdictions. The Company
is not liable if the aforementioned restrictions are not complied with by any

Certain statements, beliefs and opinions in this announcement are
forward-looking, which reflect the Company's or, as appropriate, the Company
directors' current expectations and projections concerning future events such
as the Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in which the
Company operates. By their nature, forward-looking statements involve a
number of risks, uncertainties, assumptions and other factors that could
cause actual results or events to differ materially from those expressed or
implied by the forward-looking statements. These risks, uncertainties,
assumptions and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of factors
including, but not limited to, changes in demand, competition and technology,
can cause actual events, performance or results to differ significantly from
any anticipated development. Forward-looking statements contained in this
announcement regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such trends or
activities will continue in the future. In addition, even if actual results
or developments are consistent with the forward-looking statements contained
in this announcement, those results or developments may not be indicative of
results or developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking statements.
As a result, the Company expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements in this
announcement as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such person's
officers or employees guarantees that the assumptions underlying such
forward-looking statements are free from errors nor does either accept any
responsibility for the future accuracy of the forward-looking statements
contained in this announcement or the actual occurrence of the forecasted
developments. You should not place undue reliance on forward-looking
statements, which speak only as of the date of this announcement.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ...

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.